ICUI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

542.87M

-13.8%

-0.217

-77.66%

531.70M

-11.31%

0.210

-133.33%

537.60M

-2.05%

0.335

-76.57%

Estimates Revision

The market is revising Upward the revenue expectations for ICU Medical, Inc. (ICUI) for FY2025, with the revenue forecasts being adjusted by 1.1% over the past three months. During the same period, the stock price has changed by 26.05%.

Revenue Estimates for FY2025

Revise Upward

+1.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-248.65%

In Past 3 Month

Stock Price

Go Up

+26.05%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 172.00 USD with a low forecast of 172.00 USD and a high forecast of 172.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

172.00

Averages

172.00

High

172.00

Current: 0.000

Low

172.00

Averages

172.00

High

172.00

Piper Sandler

Overweight

maintain

$153 -> $172

2025-11-07

Reason

Piper Sandler

Price Target

$153 -> $172

2025-11-07

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on ICU Medical to $172 from $153 and keeps an Overweight rating on the shares. The firm notes ICU reported Q3 results, including revenue upside across all segments, healthy margin outperformance, and a wide EPS beat. This contributed to management resetting EBITDA and EPS guidance meaningfully higher to account for the overage. Piper likes that the implied outlook for Q4 was prudently left unchanged.

KeyBanc

Overweight

maintain

$173 -> $175

2025-11-07

Reason

KeyBanc

Price Target

$173 -> $175

2025-11-07

maintain

Overweight

Reason

KeyBanc raised the firm's price target on ICU Medical to $175 from $173 on higher estimates, while keeping an Overweight rating on the shares. The firm remains encouraged by ICU's underlying operational progress as well as ability to raise 2025 EPS/EBITDA guidance, despite continued macro headwinds.

KeyBanc

Brett Fishbin

Overweight

downgrade

$191 -> $173

2025-10-21

Reason

KeyBanc

Brett Fishbin

Price Target

$191 -> $173

2025-10-21

downgrade

Overweight

Reason

KeyBanc analyst Brett Fishbin lowered the firm's price target on ICU Medical to $173 from $191 to reflect lower industry/peer multiples, while keeping an Overweight rating on the shares. The firm remains encouraged by ICU's significant progress in demonstrating increased operational and financial stability.

Piper Sandler

Jason Bednar

Overweight

maintain

$145 -> $153

2025-09-10

Reason

Piper Sandler

Jason Bednar

Price Target

$145 -> $153

2025-09-10

maintain

Overweight

Reason

Piper Sandler analyst Jason Bednar raised the firm's price target on ICU Medical to $153 from $145 and keeps an Overweight rating on the shares. One of the elements the firm liked of the ICU story when it launched coverage last month was the effects portfolio transformation could have on the business profile as it relates to the absolute financials that are reported, the growth of the asset, balance sheet leverage, and the investability of shares. The JV that deconsolidated the IV Solutions business from the ICU P&L was a major step forward, but Piper is saying today it strongly believes it's just the first step as the firm thinks ICU management may be moving forward with evaluating options for remaining pieces of the company's Vital Care portfolio, and that it's the completion of the JV just a few months ago that allows management to focus more attention on finding the best value-creating transaction for the Vital Care pieces.

Piper Sandler

Overweight

initiated

$145

2025-08-15

Reason

Piper Sandler

Price Target

$145

2025-08-15

initiated

Overweight

Reason

Piper Sandler initiated coverage of ICU Medical with an Overweight rating and $145 price target.

Piper Sandler

Jason Bednar

initiated

$145

2025-08-15

Reason

Piper Sandler

Jason Bednar

Price Target

$145

2025-08-15

initiated

Reason

As previously reported, Piper Sandler analyst Jason Bednar initiated coverage of ICU Medical with an Overweight rating and $145 price target. The infusion pump market faced regulatory and quality control challenges the last few years, and ICU has borne its own internal headwinds in the wake of the Smiths Medical transaction, the firm notes. The path to stability for the industry and ICU has been uneven and taken longer to achieve than many anticipated, but Piper believes the weight of the evidence points to ICU being in the early stages of finally showing the operational improvements necessary for margins and cash flow to take steps forward. As that improvement in fundamentals plays out, the firm sees shares as likely to recapture earnings multiple at least in the upper teens.

Valuation Metrics

The current forward P/E ratio for ICU Medical Inc (ICUI.O) is 173.53, compared to its 5-year average forward P/E of -19.61. For a more detailed relative valuation and DCF analysis to assess ICU Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-19.61

Current PE

173.53

Overvalued PE

230.61

Undervalued PE

-269.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

13.05

Current EV/EBITDA

11.26

Overvalued EV/EBITDA

14.86

Undervalued EV/EBITDA

11.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.91

Current PS

1.58

Overvalued PS

2.66

Undervalued PS

1.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ICUI News & Events

Events Timeline

No data

News

1.0

2025-12-31Globenewswire

ICU Medical to Present Innovative Products at 44th Annual J.P. Morgan Healthcare Conference

5.0

2025-11-17NASDAQ.COM

Insiders Purchase Shares of VHT ETF Holdings

6.0

2025-11-07Benzinga

Keybanc Keeps Overweight Rating on ICU Medical and Increases Price Target to $175

People Also Watch

Frequently Asked Questions

What is ICU Medical Inc (ICUI) stock price today?

The current price of ICUI is 151.65 USD — it has increased 0.88 % in the last trading day.

What is ICU Medical Inc (ICUI)'s business?

ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.

What is the price predicton of ICUI Stock?

What is ICU Medical Inc (ICUI)'s revenue for the last quarter?

ICU Medical Inc revenue for the last quarter amounts to 536.99M USD, decreased -8.85 % YoY.

What is ICU Medical Inc (ICUI)'s earnings per share (EPS) for the last quarter?

ICU Medical Inc. EPS for the last quarter amounts to -0.14 USD, decreased -89.63 % YoY.

What changes have occurred in the market's expectations for ICU Medical Inc (ICUI)'s fundamentals?

How many employees does ICU Medical Inc (ICUI). have?

ICU Medical Inc (ICUI) has 15000 emplpoyees as of January 09 2026.

What is ICU Medical Inc (ICUI) market cap?

Today ICUI has the market capitalization of 3.74B USD.